• News

Shionogi to acquire IntraBio for $2B in rare disease deal

pharminent October 6, 2026

• News

FDA approves Lilly’s Jaypirca for first-line CLL and SLL

pharminent October 5, 2026

• News

Novartis signs $7.8B Abogen deal for autoimmune T-cell engager

pharminent October 2, 2026

• News

Sanofi and Regeneron expand immunology alliance in $8B deal

pharminent October 1, 2026

• News

Novo to pay Hengrui up to $2.6B for once-weekly obesity pill

pharminent September 30, 2026

• News

AstraZeneca takes 10% Summit stake in $2B deal

pharminent September 29, 2026

• News

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo

pharminent September 28, 2026

• News

FDA advisers back Grail’s multicancer detection blood test

pharminent September 25, 2026

• News

FDA approves Lilly’s once-weekly basal insulin Onswik for type 2 diabetes

pharminent September 24, 2026

• News

Amgen’s dazodalibep meets goals in phase 3 Sjögren’s trial

pharminent September 23, 2026

• News

FDA approves Lilly’s breast cancer combination treatment

pharminent September 22, 2026

• News

Telix to acquire ITM in deal worth up to $2.35B

pharminent September 21, 2026

• News

FDA approves Ultragenyx’s gene therapy Fayuvi for Sanfilippo syndrome type A

pharminent September 18, 2026

• News

NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold

pharminent September 17, 2026

• News

Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer’s

pharminent September 16, 2026

• News

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

pharminent September 15, 2026

• News

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

pharminent September 14, 2026

• Commercial

Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand

pharminent September 14, 2026

• Regulatory

Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval

pharminent September 14, 2026

• Regulatory

Psychedelic therapies ride wave of public favor into FDA hearing

pharminent September 14, 2026

• News

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

pharminent September 11, 2026

• Manufacturing

Samsung Biologics inks $262M manufacturing deal with European pharma company

pharminent September 11, 2026

• M&A / Deals

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

pharminent September 11, 2026

• News

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

pharminent September 10, 2026

• Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026

• Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026

• M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026

• News

FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation

pharminent September 9, 2026

• Manufacturing

Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision

pharminent September 9, 2026

• News

Novartis’s Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny

pharminent September 8, 2026

• News

Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes

pharminent September 7, 2026

• M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026

• Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026

• Regulatory

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

pharminent September 7, 2026

• Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026

• News

Ionis Wins First-Ever FDA Approval for Alexander Disease with Zanvastro

pharminent September 4, 2026

• Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026

• Regulatory

Ionis nets Zanvastro US approval in first for Alexander disease

pharminent September 4, 2026

• News

Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study Stumbles

pharminent September 3, 2026

• M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026